Decision to direct share issue to Emendum AB

The Board of Directors of QuickCool AB (publ) ("QuickCool"), supported by the authorization from the annual general meeting on May 7, 2019, decided a directed share issue, with deviation from the shareholders’ preferential rights. The new share issue, that was registered with Swedish Companies Registration Office on 19 June 2019, has been addressed to Emendum AB.

Through the directed share issue, 410 000 shares have been issued which correspond to an increase in the share capital by SEK 410 000. Subscription of the shares has been made by payment. For each share, SEK 3.00 has been paid, which corresponds to a total amount of SEK 1 230 000.

The reason, for the board’s decision on a directed new issue with deviation from shareholders ' preferential rights, is related to the company’s need of liquidity. In this context, the Board of Directors considers that a decision on the issuing of shares in deviation from the shareholders ' preferential rights and with the right for Emendum AB to subscribe to the shares in the company, is justified.

The subscription price is market based and is based partly on the previous shares ' quota value, partly on the most recent average share price and partly on the company's total capital requirements.
The issue costs amount to SEK 5 000.

After the registration with the Swedish Companies Registration Office, Quickcool’s total share capital amounts to SEK 6 372 317 and the total number of shares to 6 372 317.

For additional information, please contact::
Fredrik Radencrantz, CEO

Phone: +46-46-286 38 40

This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made publicly available by the Company’s contact person on 19 June, 2019.

QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to 



Documents & Links